⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butanal SCHEMBL597713 | 1.00 | ALDH1A1 (1.00) | — | |
| Butanal SCHEMBL807 | 1.00 | — | — | |
| Butanal SCHEMBL9303364 | 1.00 | ALDH1A1 (1.00) | — | |
| Butanal SCHEMBL284804 | 0.96 | — | — | |
| Butanal SCHEMBL5604964 | 0.96 | — | — | |
| Butanal SCHEMBL23854344 | 0.96 | — | — | |
| Butanal SCHEMBL14973385 | 0.96 | — | — | |
| Butanal SCHEMBL21142995 | 0.96 | — | — | |
| Butanal SCHEMBL28908 | 0.96 | — | — | |
| Butanal SCHEMBL490038 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0520724-B1 | Angiotensin II antagonists | ZENECA LTD (GB) | 1995-09-20 | — | — | EP | claimed |
| US-5387592-A | Angiotensin converting enzyme inhibitors, calcium channel blockers, diuretics and adrenergic blocking agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-02-07 | — | — | US | claimed |
| EP-0520723-B1 | Angiotensin II antagonists | ICI PLC (GB) | 1994-06-01 | — | — | EP | claimed |
| WO-1994000450-A1 | CHROMANDERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | ZENECA LIMITED (GB) | 1994-01-06 | — | — | WO | claimed |
| WO-1993024501-A1 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSINS ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | claimed |
| WO-1993024487-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN-II-ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | claimed |
| EP-0539066-A1 | Heterocyclic compounds useful as angiotensin II antagonists | ZENECA LIMITED (GB) | 1993-04-28 | — | — | EP | claimed |
| EP-0520723-A1 | Angiotensin II antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-12-30 | — | — | EP | claimed |
| EP-0520724-A1 | Angiotensin II antagonists | ZENECA LIMITED (GB) | 1992-12-30 | — | — | EP | claimed |
| EP-0499415-A1 | Pyridine and quinoline derivatives, processes for their manufacture and their use as angiotensin II antagonists | ZENECA LIMITED (GB) | 1992-08-19 | — | — | EP | claimed |
| US-5130318-A | Hypotensive agents and for treatment of congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-14 | — | — | US | claimed |
| EP-0453210-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1991-10-23 | — | — | EP | claimed |
| EP-0520724-B1 | Angiotensin II antagonists | ZENECA LTD (GB) | 1995-09-20 | — | — | EP | disclosed |
| US-5387592-A | Angiotensin converting enzyme inhibitors, calcium channel blockers, diuretics and adrenergic blocking agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-02-07 | — | — | US | disclosed |
| US-5373015-A | Treating hypertension and congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-12-13 | — | — | US | disclosed |
| EP-0520723-B1 | Angiotensin II antagonists | ICI PLC (GB) | 1994-06-01 | — | — | EP | disclosed |
| EP-0520723-A1 | Angiotensin II antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-12-30 | — | — | EP | disclosed |
| EP-0499415-A1 | Pyridine and quinoline derivatives, processes for their manufacture and their use as angiotensin II antagonists | ZENECA LIMITED (GB) | 1992-08-19 | — | — | EP | disclosed |
| US-5130318-A | Hypotensive agents and for treatment of congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-14 | — | — | US | disclosed |
| EP-0453210-A2 | Pyridine derivatives | ZENECA LIMITED (GB) | 1991-10-23 | — | — | EP | disclosed |